Payment overview · 2025
General Payments
$3,031.16
105 reported records · 25 companies
Healthcare provider profile · identity verified
Mark W Minor, MD
Allopathic & Osteopathic Physicians|Allergy & Immunology|Allergy · MELBOURNE, FL · NPI 1982609657
Verified facts
What the public records show
CMS Open Payments records show Mark W Minor, MD received $3,031.16 in general payments during 2025 across 105 reported records.
AstraZeneca Pharmaceuticals LP accounted for 19.1% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 36 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Cuvitru, Gammaked, Hizentra, Hyqvia, Takhzyro, Xhance.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 42 claims for Symbicort by this doctor in 2024.
CSL Behring reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Hizentra as an associated drug or biological on 13634 records involving 4691 distinct recipient NPIs. Public Medicare Part D data also shows 30 claims for Hizentra by this doctor in 2024.
Kedrion Biopharma, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported GAMMAKED as an associated drug or biological on 761 records involving 541 distinct recipient NPIs. Public Medicare Part D data also shows 16 claims for Gammaked by this doctor in 2024.
Novartis Pharmaceuticals Corporation reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported XOLAIR as an associated drug or biological on 5293 records involving 2861 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Xolair by this doctor in 2024.
Optinose US, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Xhance as an associated drug or biological on 10863 records involving 5058 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Xhance by this doctor in 2024.
Paratek Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported XHANCE as an associated drug or biological on 2604 records involving 2200 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Xhance by this doctor in 2024.
Takeda Pharmaceuticals U.S.A., Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported CUVITRU as an associated drug or biological on 7118 records involving 2610 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Cuvitru by this doctor in 2024.
Takeda Pharmaceuticals U.S.A., Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported GAMMAGARD LIQUID as an associated drug or biological on 29 records involving 8 distinct recipient NPIs. Public Medicare Part D data also shows 54 claims for Gammagard Liquid by this doctor in 2024.
Takeda Pharmaceuticals U.S.A., Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported HYQVIA as an associated drug or biological on 8878 records involving 3983 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Hyqvia by this doctor in 2024.
Takeda Pharmaceuticals U.S.A., Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TAKHZYRO as an associated drug or biological on 3355 records involving 1604 distinct recipient NPIs. Public Medicare Part D data also shows 27 claims for Takhzyro by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $579.44 | 19.1% | 12 | 2025 |
| CSL Behring | Unresolved — no canonical attribution shown | $318.43 | 10.5% | 16 | 2025 |
| Takeda Pharmaceuticals U.S.A., Inc. | Unresolved — no canonical attribution shown | $257.30 | 8.5% | 10 | 2025 |
| ARS Pharmaceuticals Operations, Inc. | Unresolved — no canonical attribution shown | $251.77 | 8.3% | 10 | 2025 |
| Regeneron Healthcare Solutions, Inc. | Unresolved — no canonical attribution shown | $221.31 | 7.3% | 4 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $216.39 | 7.1% | 11 | 2025 |
| GENZYME CORPORATION | Unresolved — no canonical attribution shown | $160.74 | 5.3% | 6 | 2025 |
| ADMA BioManufacturing LLC | Unresolved — no canonical attribution shown | $152.52 | 5.0% | 2 | 2025 |
| Greer Laboratories, Inc. | Unresolved — no canonical attribution shown | $103.40 | 3.4% | 1 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $102.63 | 3.4% | 4 | 2025 |
| Optinose US, Inc. | Unresolved — no canonical attribution shown | $81.75 | 2.7% | 3 | 2025 |
| Grifols USA, LLC | Unresolved — no canonical attribution shown | $65.47 | 2.2% | 3 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $62.77 | 2.1% | 3 | 2025 |
| Ionis Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $60.67 | 2.0% | 2 | 2025 |
| Galderma Laboratories, L.P. | Unresolved — no canonical attribution shown | $58.15 | 1.9% | 3 | 2025 |
| GC Biopharma USA, Inc. | Unresolved — no canonical attribution shown | $55.16 | 1.8% | 3 | 2025 |
| Kedrion Biopharma, Inc. | Unresolved — no canonical attribution shown | $54.85 | 1.8% | 3 | 2025 |
| Insmed, Inc. | Unresolved — no canonical attribution shown | $47.03 | 1.6% | 2 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $34.00 | 1.1% | 1 | 2025 |
| BioCryst US Sales Co., LLC | Unresolved — no canonical attribution shown | $33.99 | 1.1% | 1 | 2025 |
| Cycle Pharmaceuticals Inc | Unresolved — no canonical attribution shown | $29.07 | 1.0% | 1 | 2025 |
| Incyte Corporation | Unresolved — no canonical attribution shown | $25.43 | 0.8% | 1 | 2025 |
| Azurity Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $20.43 | 0.7% | 1 | 2025 |
| Blueprint Medicines Corporation | Unresolved — no canonical attribution shown | $20.36 | 0.7% | 1 | 2025 |
| Paratek Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $18.10 | 0.6% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $2,969.64 | 103 |
| Education | $34.00 | 1 |
| Consulting Fee | $27.52 | 1 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| DUPIXENT Normalized: dupixent |
Biological | GENZYME CORPORATION, Regeneron Healthcare Solutions, Inc. | $354.25 | 8 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $276.66 | 7 | 2025 |
Source payment records
|
|||||
| NEFFY Normalized: neffy |
Drug | ARS Pharmaceuticals Operations, Inc. | $251.77 | 10 | 2025 |
Source payment records
|
|||||
| FASENRA Normalized: fasenra |
Biological | AstraZeneca Pharmaceuticals LP | $220.00 | 4 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $204.08 | 3 | 2025 |
Source payment records
|
|||||
| CUTAQUIG Normalized: cutaquig |
Biological | PFIZER INC. | $204.08 | 10 | 2025 |
Source payment records
|
|||||
| PANZYGA Normalized: panzyga |
Biological | PFIZER INC. | $186.95 | 10 | 2025 |
Source payment records
|
|||||
| HYQVIA Normalized: hyqvia |
Biological | Takeda Pharmaceuticals U.S.A., Inc. | $140.03 | 5 | 2025 |
Source payment records
|
|||||
| OCTAGAM IMMUNE GLOBULIN (HUMAN) Normalized: octagam immune globulin human |
Drug | PFIZER INC. | $135.99 | 6 | 2025 |
Source payment records
|
|||||
| Hizentra Normalized: hizentra |
Biological | CSL Behring | $120.35 | 5 | 2025 |
Source payment records
|
|||||
| Andembry Normalized: andembry |
Biological | CSL Behring | $104.22 | 5 | 2025 |
Source payment records
|
|||||
| ORALAIR Normalized: oralair |
Biological | Greer Laboratories, Inc. | $103.40 | 1 | 2025 |
Source payment records
|
|||||
| Haegarda Normalized: haegarda |
Biological | CSL Behring | $93.86 | 6 | 2025 |
Source payment records
|
|||||
| TAKHZYRO Normalized: takhzyro |
Biological | Takeda Pharmaceuticals U.S.A., Inc. | $87.77 | 4 | 2025 |
Source payment records
|
|||||
| NUCALA Normalized: nucala |
Biological | GlaxoSmithKline, LLC. | $86.00 | 3 | 2025 |
Source payment records
|
|||||
| Xhance Normalized: xhance |
Drug | Optinose US, Inc. | $81.75 | 3 | 2025 |
Source payment records
|
|||||
| Xembify Normalized: xembify |
Biological | Grifols USA, LLC | $65.47 | 3 | 2025 |
Source payment records
|
|||||
| NEMLUVIO Normalized: nemluvio |
Drug | Galderma Laboratories, L.P. | $58.15 | 3 | 2025 |
Source payment records
|
|||||
| ALYGLO Normalized: alyglo |
Drug | GC Biopharma USA, Inc. | $55.16 | 3 | 2025 |
Source payment records
|
|||||
| Albuked Normalized: albuked |
Biological | Kedrion Biopharma, Inc. | $54.85 | 3 | 2025 |
Source payment records
|
|||||
| GAMMAKED Normalized: gammaked |
Biological | Kedrion Biopharma, Inc. | $54.85 | 3 | 2025 |
Source payment records
|
|||||
| KEDRAB Normalized: kedrab |
Biological | Kedrion Biopharma, Inc. | $54.85 | 3 | 2025 |
Source payment records
|
|||||
| KOATE Normalized: koate |
Biological | Kedrion Biopharma, Inc. | $54.85 | 3 | 2025 |
Source payment records
|
|||||
| RhoGAM Ultra-Filtered PLUS Normalized: rhogam ultra filtered plus |
Biological | Kedrion Biopharma, Inc. | $54.85 | 3 | 2025 |
Source payment records
|
|||||
| DAWNZERA Normalized: dawnzera |
Drug | Ionis Pharmaceuticals, Inc. | $34.27 | 1 | 2025 |
Source payment records
|
|||||
| ORLADEYO Normalized: orladeyo |
Drug | BioCryst US Sales Co., LLC | $33.99 | 1 | 2025 |
Source payment records
|
|||||
| CUVITRU Normalized: cuvitru |
Biological | Takeda Pharmaceuticals U.S.A., Inc. | $29.50 | 1 | 2025 |
Source payment records
|
|||||
| Sajazir Normalized: sajazir |
Drug | Cycle Pharmaceuticals Inc | $29.07 | 1 | 2025 |
Source payment records
|
|||||
| AYVAKIT Normalized: ayvakit |
Biological | GENZYME CORPORATION | $27.80 | 2 | 2025 |
Source payment records
|
|||||
| OPZELURA Normalized: opzelura |
Drug | Incyte Corporation | $25.43 | 1 | 2025 |
Source payment records
|
|||||
| Brinsupri Normalized: brinsupri |
Drug | Insmed, Inc. | $24.54 | 1 | 2025 |
Source payment records
|
|||||
| Rhapsido Normalized: rhapsido |
Drug | Novartis Pharmaceuticals Corporation | $24.38 | 1 | 2025 |
Source payment records
|
|||||
| Arikayce Normalized: arikayce |
Drug | Insmed, Inc. | $22.49 | 1 | 2025 |
Source payment records
|
|||||
| ALVESCO Normalized: alvesco |
Drug | Azurity Pharmaceuticals, Inc. | $20.43 | 1 | 2025 |
Source payment records
|
|||||
| NUZYRA Normalized: nuzyra |
Drug | Paratek Pharmaceuticals, Inc. | $18.10 | 1 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $16.63 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| CUVITRU cuvitru |
2025 | Cuvitru | 2024 | 13 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| GAMMAKED gammaked |
2025 | Gammaked | 2024 | 16 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Hizentra hizentra |
2025 | Hizentra | 2024 | 30 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| HYQVIA hyqvia |
2025 | Hyqvia | 2024 | 13 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| TAKHZYRO takhzyro |
2025 | Takhzyro | 2024 | 27 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Xhance xhance |
2025 | Xhance | 2024 | 11 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
42 | 14 |
| CSL Behring Exact reporting entity; no affiliate inference |
2025 | Hizentra open payments reported associated product |
CMS Open Payments — General Payments 13634 supporting records · 4691 recipient NPIs · example record 1232339012 |
Hizentra · 2024 Exact normalized brand match · 1 Part D row |
30 | suppressed by CMS |
| Kedrion Biopharma, Inc. Exact reporting entity; no affiliate inference |
2025 | GAMMAKED open payments reported associated product |
CMS Open Payments — General Payments 761 supporting records · 541 recipient NPIs · example record 1206766586 |
Gammaked · 2024 Exact normalized brand match · 1 Part D row |
16 | suppressed by CMS |
| Novartis Pharmaceuticals Corporation Exact reporting entity; no affiliate inference |
2025 | XOLAIR open payments reported associated product |
CMS Open Payments — General Payments 5293 supporting records · 2861 recipient NPIs · example record 1200005083 |
Xolair · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| Optinose US, Inc. Exact reporting entity; no affiliate inference |
2025 | Xhance open payments reported associated product |
CMS Open Payments — General Payments 10863 supporting records · 5058 recipient NPIs · example record 1163252000 |
Xhance · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| Paratek Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | XHANCE open payments reported associated product |
CMS Open Payments — General Payments 2604 supporting records · 2200 recipient NPIs · example record 1181734372 |
Xhance · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| Takeda Pharmaceuticals U.S.A., Inc. Exact reporting entity; no affiliate inference |
2025 | CUVITRU open payments reported associated product |
CMS Open Payments — General Payments 7118 supporting records · 2610 recipient NPIs · example record 1223616510 |
Cuvitru · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| Takeda Pharmaceuticals U.S.A., Inc. Exact reporting entity; no affiliate inference |
2025 | GAMMAGARD LIQUID open payments reported associated product |
CMS Open Payments — General Payments 29 supporting records · 8 recipient NPIs · example record 1223786557 |
Gammagard Liquid · 2024 Exact normalized brand match · 1 Part D row |
54 | suppressed by CMS |
| Takeda Pharmaceuticals U.S.A., Inc. Exact reporting entity; no affiliate inference |
2025 | HYQVIA open payments reported associated product |
CMS Open Payments — General Payments 8878 supporting records · 3983 recipient NPIs · example record 1223616272 |
Hyqvia · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| Takeda Pharmaceuticals U.S.A., Inc. Exact reporting entity; no affiliate inference |
2025 | TAKHZYRO open payments reported associated product |
CMS Open Payments — General Payments 3355 supporting records · 1604 recipient NPIs · example record 1223616316 |
Takhzyro · 2024 Exact normalized brand match · 1 Part D row |
27 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Montelukast Sodium | Montelukast Sodium | 132 | 40 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 114 | 38 |
| Azelastine Hcl | Azelastine Hcl | 84 | 43 |
| Fluticasone Propionate | Fluticasone Propionate | 67 | 30 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 60 | 13 |
| Gammagard Liquid | Immun Glob G(Igg)/Gly/Iga Ov50 | 54 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 53 | 14 |
| Advair Hfa | Fluticasone Propion/Salmeterol | 51 | suppressed |
| Sodium Chloride | 0.9 % Sodium Chloride | 47 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 46 | suppressed |
| Famotidine | Famotidine | 45 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 42 | 14 |
| Spiriva Respimat | Tiotropium Bromide | 40 | 11 |
| Ipratropium Bromide | Ipratropium Bromide | 38 | 17 |
| Epinephrine | Epinephrine | 35 | 28 |
| Hizentra | Immun Glob G(Igg)/Pro/Iga 0-50 | 30 | suppressed |
| Azithromycin | Azithromycin | 27 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 27 | 13 |
| Takhzyro | Lanadelumab-Flyo | 27 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 26 | 16 |
| Prednisolone | Prednisolone | 24 | 16 |
| Qvar Redihaler | Beclomethasone Dipropionate | 24 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 23 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 18 | suppressed |
| Dulera | Mometasone/Formoterol | 17 | suppressed |
| Fluticasone Propionate Hfa | Fluticasone Propionate | 17 | suppressed |
| Gammaked | Immune Globul G/Gly/Iga Avg 46 | 16 | suppressed |
| Mometasone Furoate | Mometasone Furoate | 16 | suppressed |
| Albuterol Sulfate | Albuterol Sulfate | 15 | suppressed |
| Arnuity Ellipta | Fluticasone Furoate | 14 | suppressed |
| Incruse Ellipta | Umeclidinium Bromide | 14 | suppressed |
| Prednisolone Sodium Phosphate | Prednisolone Sodium Phosphate | 14 | 12 |
| Cuvitru | Immun Glob G(Igg)/Gly/Iga Ov50 | 13 | suppressed |
| Dupixent Syringe | Dupilumab | 13 | suppressed |
| Hyqvia | Igg/Hyaluronidase,recombinant | 13 | suppressed |
| Xolair | Omalizumab | 13 | suppressed |
| Olopatadine Hcl | Olopatadine Hcl | 12 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 11 | suppressed |
| Breyna | Budesonide/Formoterol Fumarate | 11 | suppressed |
| Dupixent Pen | Dupilumab | 11 | suppressed |
| Xhance | Fluticasone Propionate | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $3,031.16 · 105 records | AstraZeneca Pharmaceuticals LP | AIRSUPRA, ALVESCO, ALYGLO, AYVAKIT, Albuked, Andembry, Arikayce, BREZTRI, Brinsupri, CUTAQUIG, CUVITRU, DAWNZERA, DUPIXENT, FASENRA, GAMMAKED, HYQVIA, Haegarda, Hizentra, KEDRAB, KOATE, NEFFY, NEMLUVIO, NUCALA, NUZYRA, OCTAGAM IMMUNE GLOBULIN (HUMAN), OPZELURA, ORALAIR, ORLADEYO, PANZYGA, Rhapsido, RhoGAM Ultra-Filtered PLUS, Sajazir, TAKHZYRO, TRELEGY ELLIPTA, Xembify, Xhance | 10 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Cuvitru play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with AstraZeneca Pharmaceuticals LP?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error